LANCASTER, Calif.--(BUSINESS WIRE)--
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, chemicals, and consumer goods industries, today announced that it has released version 2 of its in vitro data analysis program, MembranePlus™.
John DiBella, vice president for marketing and sales for Simulations Plus, said: “For over 20 years, significant research has been devoted to in vitro permeability and hepatocyte systems, with several guidelines being published and all pharmacopeia describing appropriate methods for testing. These experiments are expensive and, quite often, pharmaceutical researchers overlook key processes when analyzing their results. The improvements in this version of MembranePlus make it easier to model companies’ data and unlock important insights from common membrane assays. This leads to improved in vitro-in vivo extrapolation (IVIVE) predictions when transferred to GastroPlus™ models, which is a hot topic in the industries we serve. Already, a number of companies are requesting evaluation licenses, and we are excited for them to recognize the value MembranePlus will provide, both by improving the efficiency of their data analysis and the accuracy of their GastroPlus simulations.”
James Mullin, Principal Scientist and MembranePlus product manager, added: “The enhancements found in MembranePlus 2 include: new mechanistic models for in vitro hepatocyte assays (sandwich and suspended); new estimation methods for key parameters to better inform GastroPlus models; enhancements to the optional ADMET Predictor™ Module; and improved output reporting for all simulation modes. We expect these program enhancements to benefit a broad range of GastroPlus customers from discovery scientists to DMPK researchers and CROs.”
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemicals, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170823005542/en/
